Press Release – New York, NY – October 3, 2020 – Sichenzia Ross Ference LLP announced today that it represented Laidlaw & Company (UK) Ltd. in the $5.75 million initial public offering and Nasdaq uplisting of Silo Pharma, Inc. (Nasdaq: SILO), a developmental stage biopharmaceutical company focused on merging traditional therapeutics with psychedelic research. 1,150,000 shares of common stock, which included the full exercise of the underwriters’ over-allotment option, were sold to the public at a price of $5.00 per share. Silo Pharma’s common stock began trading on the Nasdaq Capital Market under the ticker symbol “SILO” on September 27, 2022.
Laidlaw & Company (UK) Ltd. acted as the sole book-running manager for the offering. The Benchmark Company, LLC acted as the co-manager for the offering.
The Sichenzia Ross Ference LLP team was led by partners Michael Ference and Barrett DiPaolo and associates Matt Siracusa and Kayla Scoccola.
[starbox id=1]
